Holen Sie sich die Stockscreener-App
42.78
2.92%
1.215
Handel nachbörslich:
42.77
-0.015
-0.04%
Schlusskurs vom Vortag:
$41.57
Offen:
$42
24-Stunden-Volumen:
1.83M
Relative Volume:
0.66
Marktkapitalisierung:
$11.11B
Einnahmen:
$2.32B
Nettoeinkommen (Verlust:
$782.57M
KGV:
15.37
EPS:
2.7838
Netto-Cashflow:
$875.84M
1W Leistung:
+3.70%
1M Leistung:
-4.39%
6M Leistung:
+10.58%
1J Leistung:
+13.46%
1-Tages-Spanne:
$41.87
$43.48
1-Wochen-Bereich:
$40.84
$43.48
52-Wochen-Spanne:
$32.38
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
42.78 | 10.80B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
EXEL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quarterly Trades: Will Exelixis Inc outperform its industry peersMarket Volume Report & Capital Protection Trade Alerts - baoquankhu1.vn
Private Client Services LLC Takes $1.99 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Here's why Exelixis (EXEL) is a strong value stock - MSN
Strategic Investment Advisors MI Buys 27,659 Shares of Exelixis, Inc. $EXEL - MarketBeat
How Exelixis Inc. (EXEL) Affects Rotational Strategy Timing - Stock Traders Daily
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis GrowthNews and Statistics - IndexBox
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
The Best Healthcare Stocks to Buy With $50 Right Now - The Motley Fool
Portfolio Update: What is the earnings history of Exelixis Inc2026 Highlights & AI Powered Trade Plan Recommendations - baoquankhu1.vn
L2 Asset Management LLC Invests $3.36 Million in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion - Yahoo Finance
Exelixis, Inc. $EXEL Shares Acquired by Clark Capital Management Group Inc. - MarketBeat
Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink - MarketBeat
Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference - MarketBeat
Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference - MarketBeat
Exelixis Inc Stock (ISIN: US30161Q1040) Gains Momentum on Earnings Beat and Zanzalintinib FDA Milest - AD HOC NEWS
Capital Impact Advisors LLC Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat
How Exelixis’ Earnings Beat and FDA Zanzalintinib Milestone Will Impact Exelixis (EXEL) Investors - simplywall.st
Exelixis, Inc. $EXEL Stake Raised by South Street Advisors LLC - MarketBeat
Exelixis (NASDAQ:EXEL) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
EXEL SEC FilingsExelixis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts - simplywall.st
Schroder Investment Management Group Has $22.95 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Here’s What Makes Exelixis (EXEL) a Top Growth Stock - Bitget
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights By Investing.com - Investing.com Canada
EXEL: Zanzalintinib and CABOMETYX anchor growth in GI/GU oncology, with robust pipeline momentum - TradingView
EXEL: Zanza and new indications drive growth, targeting $2.4B revenue and leadership in key oncology markets - TradingView
First Trust Advisors LP Has $59.35 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Barclays PLC Boosts Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC - Investing.com Canada
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com Nigeria
Dimensional Fund Advisors LP Grows Holdings in Exelixis, Inc. $EXEL - MarketBeat
Victory Capital Management Inc. Acquires 187,034 Shares of Exelixis, Inc. $EXEL - MarketBeat
What is Zacks Research's Estimate for Exelixis Q3 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
(EXEL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Teton Advisors LLC Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Cut to Hold at Zacks Research - MarketBeat
Gainers Report: Will Exelixis Inc benefit from rising consumer demandWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Hold" by Analysts - MarketBeat
American Century Companies Inc. Raises Position in Exelixis, Inc. $EXEL - MarketBeat
Elo Mutual Pension Insurance Co Buys 30,279 Shares of Exelixis, Inc. $EXEL - MarketBeat
A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st
EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):